SCHEMBL5121069

SCHEMBL5121069

Cc1cccc(C[C@@H](N)[CH]CNCCC(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TAAR1 Q96RJ0 2/20 0.36
▸ IDO1 P14902 2/20 0.36
▸ ANPEP P15144 2/20 0.35
▸ RNPEP Q9H4A4 2/20 0.35
▸ DNPEP Q9ULA0 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PNMT P11086 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ LAP3 P28838 4/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CNR1 P21554 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117837 0.86 SIGMAR1 (0.42) TAAR1IDO1ANPEPRNPEPDNPEP
SCHEMBL5125276 0.83 POLB (0.36) HPGDTAAR1ANPEPRNPEPDNPEP
SCHEMBL5121072 0.81 HPGD (0.42) HPGDSMN1; SMN2TAAR1IDO1ANPEP
SCHEMBL6172030 0.80 GLS (0.43) TAAR1CNR1
SCHEMBL11983501 0.78 ALDH1A1 (0.49) HPGDSMN1; SMN2TAAR1IDO1MEN1
SCHEMBL5121369 0.77 SLC6A2 (0.47) TAAR1ANPEPRNPEPDNPEPMEN1
SCHEMBL5117675 0.77 TRPA1 (0.37) HPGDTAAR1ANPEPRNPEPDNPEP
SCHEMBL27633021 0.76 TAAR1 (0.57) TAAR1MEN1KMT2AALDH1A1CYP2D6
SCHEMBL8346882 0.74 TAAR1 (0.47) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL6173496 0.72 LTA4H (0.37) SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 — — US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 HPGD 1263/4885SMN1; SMN2 154/4885TAAR1 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback